By Colin Kellaher

Merck & Co. on Tuesday said the U.S. Food and Drug Administration approved the expanded use of its antiviral agent Prevymis against a common viral infection experienced by transplant recipients.

The Kenilworth, N.J., drugmaker said the approval covers Prevymis for the prevention of cytomegalovirus disease in adult kidney transplant recipients at high risk.

Prevymis, which the FDA first approved in 2017, generated revenue of $428 million last year.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

June 06, 2023 07:32 ET (11:32 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Merck Charts.